Cover Image
市場調查報告書

EpiCast Report:全球血脂異常症的流行病學預測

EpiCast Report: Dyslipidemia - Epidemiology Forecast to 2023

出版商 GlobalData 商品編碼 262489
出版日期 內容資訊 英文 94 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast Report:全球血脂異常症的流行病學預測 EpiCast Report: Dyslipidemia - Epidemiology Forecast to 2023
出版日期: 2014年10月15日 內容資訊: 英文 94 Pages
簡介

全球主要8個國家血脂異常症的患病人數,預測將從2013年的5億7241萬8492人,以年平均成長率(CAGR)1.99%的速度增加,到2023年增加到6億85905635人。除了德國之外的所有國家,血脂異常症的患病人數都有增加趨勢。此外到2023年,預測家族性高膽固醇血症(FH)的患病人數將達436萬5831名、高LDL膽固醇血症將達4億1173萬7455、超高甘油三酯血症(TG)將達1274萬6492名。

本報告提供全球主要8個國家(美國·德國·法國·義大利·西班牙·英國·日本·中國)的血脂異常症發病情形與今後預測相關分析,提供血脂異常症的特徵,及各國的詳細情況,今後10年的發病數量預測值等調查評估,並將其結果為您概述為以下內容。

第1章 目錄

第2章 簡介

第3章 流行病學

  • 疾病的背景
  • 風險要素和共生病症
  • 全球各國各地趨勢
    • 美國
    • 歐洲主要5個國家
    • 亞洲
  • 預測手法
    • 利用之資訊來源
    • 未利用之資訊來源
    • 預測的前提條件與手法
  • 血脂異常症的流行病學預測(今後10年份)
    • 血脂異常症的患病者總數
    • 各年齡層的患病人數
    • 男女的患病人數
    • 年齡已調整的患病者總數
  • 家族性高膽固醇血症的流行病學預測(今後10年份)
    • 家族性高膽固醇血症的患病者總數
  • 高LDL膽固醇血症的流行病學預測(今後10年份)
    • 高LDL膽固醇血症的患病者總數
    • 各年齡層的患病人數
    • 男女的患病人數
    • 年齡已調整的患病者總數
  • 超高甘油三酯血症(TG)的流行病學預測(今後10年份)
    • 超高甘油三酯血症的患病者總數
    • 各年齡層的患病人數
    • 男女的患病人數
    • 年齡已調整的患病者總數
  • 議論
    • 流行病學的趨勢相關考察
    • 分析的限制
    • 分析的優勢

第4章 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHCER004-14

Dyslipidemia is a condition in which one or more of the serum lipid levels are abnormal. It is a well-established risk factor for cardiovascular disease, and the burden of morbidity, mortality, and medical costs arising from dyslipidemia is substantial.

GlobalData epidemiologists forecast that the total prevalent cases of dyslipidemia in the 8MM will increase from 572,418,492 total prevalent cases in 2013, to 685,905,635 total prevalent cases in 2023, at an Annual Growth Rate (AGR) of 1.99%. All markets will see an increase in the total prevalent cases of dyslipidemia at varying AGRs, except for Germany, which will see a decrease. The 8MM had an estimated 3,339,447 total prevalent cases of FH in 2013, and the number of total prevalent cases of FH is expected to increase to 4,365,831 by 2023, at an AGR of 3.07%. All markets will see an increase in the total prevalent cases of FH at varying AGRs, except for Japan, which will see a decrease. Additionally, GlobalData epidemiologists forecast that the total prevalent cases of increased LDLc in the 8MM will increase from 345,008,543 total prevalent cases in 2013 to 411,737,455 total prevalent cases in 2023, at an AGR of 1.93%. All markets will see an increase in the total prevalent cases of increased LDLc at varying AGRs, except for Germany, which will see a decrease. The 8MM had an estimated 10,777,756 total prevalent cases of very high TG (=500mg/dL) in 2013, and the number of total prevalent cases of very high TG is expected to increase to 12,746,492 by 2023, at an AGR of 1.83%. All markets will see an increase in the total prevalent cases of very high TG at varying AGRs, except for Germany and Japan, which will see a decrease.

GlobalData epidemiologists used comprehensive, country-specific data from population based national health surveys such as NHANES in the US, the HSE in the UK, and the CHNS in urban China, in addition to data from peer-reviewed journal articles, to arrive at a meaningful, in-depth analysis and forecast for the total prevalent cases of dyslipidemia, and other therapeutically significant patient populations including the total prevalent cases of increased LDLc and very high TG (=500mg/dL). For all the 8MM, the total prevalent cases of dyslipidemia, increased LDLc, and very high TG (=500mg/dL) were segmented by age and sex, which facilitates an understanding of the distribution of disease within the population, and informs strategies to improve the management of disease.

Scope

  • The Dyslipidemia EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for dyslipidemia in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and China [urban]). It includes a 10-year epidemiological forecast for the total prevalent cases of dyslipidemia (defined as: increased low-density lipoprotein cholesterol [LDLc], high triglycerides [TG] [=200mg/dL], or low levels of high-density lipoprotein cholesterol [HDLc]), as well as the total prevalent cases of increased LDLc (=115mg/dL to =160mg/dL based on country-specific cut-offs), and very high TG (=500mg/dL), segmented by sex and age (in 10-year intervals beginning at 20 years and ending at =70 years). Additionally, the forecast provides the total prevalent cases of familial hypercholesterolemia (FH) in these markets.
  • The dyslipidemia epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to buy

  • Develop business strategies by understanding the trends shaping and driving the global dyslipidemia market.
  • Quantify patient populations in the global dyslipidemia market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for dyslipidemia therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global Trends
    • 3.3.1. US
    • 3.3.2. 5EU
    • 3.3.3. Asia
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods
  • 3.5. Epidemiological Forecast for Dyslipidemia (2013-2023)
    • 3.5.1. Total Prevalent Cases of Dyslipidemia
    • 3.5.2. Age-Specific Total Prevalent Cases of Dyslipidemia
    • 3.5.3. Sex-Specific Total Prevalent Cases of Dyslipidemia
    • 3.5.4. Age-Standardized Total Prevalence of Dyslipidemia
  • 3.6. Epidemiological Forecast for Familial Hypercholesterolemia (2013-2023)
    • 3.6.1. Total Prevalent Cases of Familial Hypercholesterolemia
  • 3.7. Epidemiological Forecast for Increased LDLc (2013-2023)
    • 3.7.1. Total Prevalent Cases of Increased LDLc
    • 3.7.2. Age-Specific Total Prevalent Cases of Increased LDLc
    • 3.7.3. Sex-Specific Total Prevalent Cases of Increased LDLc
    • 3.7.4. Age-Standardized Total Prevalence of Increased LDLc
  • 3.8. Epidemiological Forecast for Very High TG (≥500mg/dL) (2013-2023)
    • 3.8.1. Total Prevalent Cases of Very High TG (≥500mg/dL)
    • 3.8.2. Age-Specific Total Prevalent Cases of Very High TG (≥500mg/dL)
    • 3.8.3. Sex-Specific Total Prevalent Cases of Very High TG (≥500mg/dL)
    • 3.8.4. Age-Standardized Total Prevalence of Very High TG (≥500mg/dL)
  • 3.9. Discussion
    • 3.9.1. Epidemiological Forecast Insight
    • 3.9.2. Limitations of the Analysis
    • 3.9.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Acting Director of Epidemiology
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities for Dyslipidemia
  • Table 2: Overview of the Total Prevalence of Low HDLc in the 5EU
  • Table 3: NCEP-ATP III Classification of LDLc, TG, and HDLc
  • Table 4: Simon Broome Diagnostic Criteria for FH
  • Table 5: LDLc Based Definition of FH
  • Table 6: Sources of Total Prevalence Data for FH in the 8MM
  • Table 7: Sources of Total Prevalence Data for Increased LDLc in the 8MM
  • Table 8: Sources of Total Prevalence Data for High TG (≥200mg/dL) in the 8MM
  • Table 9: Sources of Total Prevalence Data for Very High TG (≥500mg/dL) in the 8MM
  • Table 10: Sources of Total Prevalence Data for Low HDLc in the 8MM
  • Table 11: 8MM, Sources Not Used in the Epidemiological Analysis of Dyslipidemia
  • Table 12: 8MM, Total Prevalent Cases of Dyslipidemia, Both Sexes, Ages ≥20 Years, N, 2013-2023
  • Table 13: 8MM, Age-Specific Total Prevalent Cases of Dyslipidemia, Both Sexes, N (Row %), 2013
  • Table 14: 8MM, Sex-Specific Total Prevalent Cases of Dyslipidemia, Ages ≥20 Years, N (Row %), 2013
  • Table 15: 8MM, Total Prevalent Cases of Familial Hypercholesterolemia, Both Sexes, Ages ≥20 Years, N, 2013-2023
  • Table 16: 8MM, Total Prevalent Cases of Increased LDLc* (≥115mg/dL to ≥160mg/dL), Both Sexes, Ages ≥20 Years, N, 2013-2023
  • Table 17: 8MM, Age-Specific Total Prevalent Cases of Increased LDLc* (≥115mg/dL to ≥160mg/dL), Both Sexes, N (Row %), 2013
  • Table 18: 8MM, Sex-Specific Total Prevalent Cases of Increased LDLc* (≥115mg/dL to ≥160mg/dL), Ages ≥20 Years, N (Row %), 2013
  • Table 19: 8MM, Total Prevalent Cases of Very High TG (≥500mg/dL), Both Sexes, Ages ≥20 Years, N, 2013-2023
  • Table 20: 8MM, Age-Specific Total Prevalent Cases of Very High TG (≥500mg/dL), Both Sexes, N (Row %), 2013
  • Table 21: 8MM, Sex-Specific Total Prevalent Cases of Very High TG (≥500mg/dL), Ages ≥20 Years, N (Row %), 2013

List of Figures

  • Figure 1: 8MM, Total Prevalent Cases of Dyslipidemia, Both Sexes, Ages ≥20 Years, N, 2013-2023
  • Figure 2: 8MM, Age-Specific Total Prevalent Cases of Dyslipidemia, Both Sexes, Ages ≥20 Years, N, 2013
  • Figure 3: 8MM, Sex-Specific Total Prevalent Cases of Dyslipidemia, Ages ≥20 Years, N, 2013
  • Figure 4: 8MM, Age-Standardized Total Prevalence of Dyslipidemia (%), Ages ≥20 Years, by Sex, 2013
  • Figure 5: 8MM, Total Prevalent Cases of Familial Hypercholesterolemia, Both Sexes, Ages ≥20 Years, N, 2013-2023
  • Figure 6: 8MM, Total Prevalent Cases of Increased LDLc* (≥115mg/dL to ≥160mg/dL), Both Sexes, Ages ≥20 Years, N, 2013-2023
  • Figure 7: 8MM, Age-Specific Total Prevalent Cases of Increased LDLc* (≥115mg/dL to ≥160mg/dL), Both Sexes, Ages ≥20 Years, N, 2013
  • Figure 8: 8MM, Sex-Specific Total Prevalent Cases of Increased LDLc* (≥115mg/dL to ≥160mg/dL), Ages ≥20 Years, N, 2013
  • Figure 9: 8MM, Age-Standardized Total Prevalence of Increased LDLc (≥115mg/dL to ≥160mg/dL)* (%), Ages ≥20 Years, by Sex, 2013
  • Figure 10: 8MM, Total Prevalent Cases of Very High TG (≥500mg/dL), Both Sexes, Ages ≥20 Years, N, 2013-2023
  • Figure 11: 8MM, Age-Specific Total Prevalent Cases of Very High TG (≥500mg/dL), Both Sexes, Ages ≥20 Years, N, 2013
  • Figure 12: 8MM, Sex-Specific Total Prevalent Cases of Very High TG (≥500mg/dL), Ages ≥20 Years, N, 2013
  • Figure 13: 8MM, Age-Standardized Total Prevalence of Very High TG (≥500mg/dL) (%), Ages ≥20 Years, by Sex, 2013
Back to Top